115 related articles for article (PubMed ID: 32487632)
1. Spleen Volume as a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
Miyata T; Takamura H; Kin R; Nishiki H; Hashimoto A; Fujii Y; Miura S; Fujita J; Kaida D; Tomita Y; Nakamura N; Fujita H; Kinami S; Ueda N; Kosaka T
Anticancer Res; 2020 Jun; 40(6):3361-3370. PubMed ID: 32487632
[TBL] [Abstract][Full Text] [Related]
2. Risk Factors for Thrombocytopenia Induced by Capecitabine Plus Oxaliplatin Therapy in Patients With Colorectal Cancer.
Kato N; Nakai T; Kodama S; Koyama S; Nakane S; Wada Y; Oda H; Katayama H; Mase H; Miyagawa Y; Miyazaki M; Yamada S; Yamada K
In Vivo; 2024; 38(3):1243-1252. PubMed ID: 38688620
[TBL] [Abstract][Full Text] [Related]
3. Hyaluronic Acid May Be a Predictive Biomarker for Thrombocytopenia and Liver Dysfunction After Oxaliplatin-based Chemotherapy.
Miyata T; Tomita Y; San-Nomiya Y; Nagayama T; Kin R; Nishiki H; Hashimoto A; Fujii Y; Miura S; Kaida D; Nakamura N; Miyashita T; Fujita H; Ueda N; Takamura H
Cancer Diagn Progn; 2022; 2(1):15-24. PubMed ID: 35400001
[TBL] [Abstract][Full Text] [Related]
4. The Addition of Bevacizumab to Oxaliplatin-Based Chemotherapy: Impact Upon Hepatic Sinusoidal Injury and Thrombocytopenia.
Overman MJ; Ferrarotto R; Raghav K; George B; Qiao W; Machado KK; Saltz LB; Mazard T; Vauthey JN; Hoff PM; Hobbs B; Loyer EM; Kopetz S
J Natl Cancer Inst; 2018 Aug; 110(8):888-894. PubMed ID: 29346573
[TBL] [Abstract][Full Text] [Related]
5. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for first-line treatment of patients with metastatic colorectal cancer: a randomised, non-inferiority phase 3 trial.
Hong YS; Park YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Jo SJ; Lee JW
Lancet Oncol; 2012 Nov; 13(11):1125-32. PubMed ID: 23062232
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury.
Overman MJ; Maru DM; Charnsangavej C; Loyer EM; Wang H; Pathak P; Eng C; Hoff PM; Vauthey JN; Wolff RA; Kopetz S
J Clin Oncol; 2010 May; 28(15):2549-55. PubMed ID: 20406923
[TBL] [Abstract][Full Text] [Related]
7. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer.
Wong GG; Ha V; Chu MP; Dersch-Mills D; Ghosh S; Chambers CR; Sawyer MB
Clin Colorectal Cancer; 2019 Mar; 18(1):72-79. PubMed ID: 30551953
[TBL] [Abstract][Full Text] [Related]
8. Protocol of a randomised phase III clinical trial of sequential capecitabine or 5-fluorouracil plus bevacizumab (Cape/5-FU-Bmab) to capecitabine or 5-fluorouracil plus oxaliplatin plus bevacizumab (CapeOX/mFOLFOX6-Bmab) versus combination CapeOX/mFOLFOX6-Bmab in advanced colorectal cancer: the C-cubed (C3) study.
Nagasaka T; Mishima H; Sawaki A; Shimokawa M; Inukai M; Shinozaki K; Tanioka H; Nasu J; Nishina T; Hazama S; Okajima M; Yamaguchi Y
BMJ Open; 2016 Jun; 6(6):e011454. PubMed ID: 27256093
[TBL] [Abstract][Full Text] [Related]
9. A case of idiosyncratic liver injury after oxaliplatin-induced thrombocytopenia.
Honda S; Tsujimoto M; Minegaki T; Mori T; Muraoka J; Nishiguchi K
J Clin Pharm Ther; 2020 Apr; 45(2):373-375. PubMed ID: 31671217
[TBL] [Abstract][Full Text] [Related]
10. S-1 plus oxaliplatin versus capecitabine plus oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: updated results from a phase 3 trial.
Kim ST; Hong YS; Lim HY; Lee J; Kim TW; Kim KP; Kim SY; Baek JY; Kim JH; Lee KW; Chung IJ; Cho SH; Lee KH; Shin SJ; Kang HJ; Shin DB; Lee JW; Jo SJ; Park YS
BMC Cancer; 2014 Nov; 14():883. PubMed ID: 25424120
[TBL] [Abstract][Full Text] [Related]
11. Splenic volume may be a useful indicator of the protective effect of bevacizumab against oxaliplatin-induced hepatic sinusoidal obstruction syndrome.
Imai K; Emi Y; Iyama KI; Beppu T; Ogata Y; Kakeji Y; Samura H; Oki E; Akagi Y; Maehara Y; Baba H;
Eur J Surg Oncol; 2014 May; 40(5):559-566. PubMed ID: 24388740
[TBL] [Abstract][Full Text] [Related]
12. Predictive factors of collateral vessel development induced by oxaliplatin-based chemotherapy.
Mukai K; Nishida T; Matsumoto K; Kitanaka T; Hosokawa K; Sakamoto N; Okabe S; Fujii Y; Osugi N; Sugimoto A; Nakamatsu D; Yamamoto M; Fukui K
Int J Clin Oncol; 2023 Feb; 28(2):280-288. PubMed ID: 36586029
[TBL] [Abstract][Full Text] [Related]
13. Splenomegaly in Colon Cancer During Adjuvant Oxaliplatin-based Chemotherapy.
Eren T; Pasaoglu L
Cureus; 2020 Mar; 12(3):e7230. PubMed ID: 32280572
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.
Saito R; Kawamoto Y; Nishida M; Iwai T; Kikuchi Y; Yokota I; Takagi R; Yamamura T; Ito K; Harada K; Yuki S; Komatsu Y; Sakamoto N
Int J Clin Oncol; 2022 Nov; 27(11):1780-1790. PubMed ID: 36042137
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab improves splenomegaly and decreases production of hyaluronic acid after L-OHP based chemotherapy.
Arakawa Y; Shimada M; Utsunomiya T; Imura S; Morine Y; Ikemoto T; Hanaoka J; Kanamoto M; Iwahashi S; Saito Y; Yamada S; Asanoma M; Takasu C; Bando Y
Anticancer Res; 2014 Apr; 34(4):1953-8. PubMed ID: 24692731
[TBL] [Abstract][Full Text] [Related]
16. Splenomegaly and Its Associations with Genetic Polymorphisms and Treatment Outcome in Colorectal Cancer Patients Treated with Adjuvant FOLFOX.
Kim MJ; Han SW; Lee DW; Cha Y; Lee KH; Kim TY; Oh DY; Kim SH; Im SA; Bang YJ; Kim TY
Cancer Res Treat; 2016 Jul; 48(3):990-7. PubMed ID: 26790967
[TBL] [Abstract][Full Text] [Related]
17. Predicting high grade lesions of sinusoidal obstruction syndrome related to oxaliplatin-based chemotherapy for colorectal liver metastases: correlation with post-hepatectomy outcome.
Soubrane O; Brouquet A; Zalinski S; Terris B; Brézault C; Mallet V; Goldwasser F; Scatton O
Ann Surg; 2010 Mar; 251(3):454-60. PubMed ID: 20160638
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin-induced increase in splenic volume; irreversible change after adjuvant FOLFOX.
Iwai T; Yamada T; Koizumi M; Shinji S; Yokoyama Y; Takahashi G; Takeda K; Hara K; Ohta K; Uchida E
J Surg Oncol; 2017 Dec; 116(7):947-953. PubMed ID: 28876454
[TBL] [Abstract][Full Text] [Related]
19. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902).
Nakayama G; Ishigure K; Yokoyama H; Uehara K; Kojima H; Ishiyama A; Hayashi N; Takano N; Hattori N; Kobayashi D; Tanaka C; Hayashi M; Kanda M; Yamada S; Sugimoto H; Koike M; Fujiwara M; Fujii T; Murotani K; Ando Y; Kodera Y
BMC Cancer; 2017 Apr; 17(1):243. PubMed ID: 28376737
[TBL] [Abstract][Full Text] [Related]
20. Treatment of Gastric and Gastroesophageal Cancer Patients with Hemodialysis by CapeOX.
Sasaki K; Zhou Q; Matsumoto Y; Saiki T; Moriyama M; Saijo Y
Intern Med; 2019 Oct; 58(19):2791-2795. PubMed ID: 31243213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
